JANUARY 14, 2022
- The Facts: A landmark paper published in 2018 showing high amounts of aluminum in autistic brains has now been downloaded more than 1 million times.
- Reflect On: Why is it taboo to present science that calls into question and threatens the safety profile of certain medicines? Can science be openly practiced today with the enormous control the industry has over federal health regulatory agencies as well as academia?
In 2018, Professor of Bioinorganic Chemistry at Keele University Christopher Exley, who is considered one of the world’s leading experts in aluminum toxicology, published a paper in the Journal of Trace Elements in Medicine & Biology showing very high amounts of aluminum in the brain tissues of people with autism.
Exley has examined more than 100 brains, and the aluminum content in these people is some of the highest he has ever seen and raises new questions about the role of aluminum in the etiology of autism. Five people were used in the study, comprising of four males and one female, all between the ages of 14-50. Each of their brains contained what the authors considered unsafe and high amounts of aluminum compared to brain tissues of patients with other diseases where high brain aluminum content is common, like Alzheimer’s disease, for example.
Help Support Our FOI Efforts: We are holding the Canadian government accountable by submitting Freedom of Information requests demanding transparency on COVID policy decisions as we know science is not on the side of policy. Help us fund these efforts by donating today. Click here to Donate.
It’s now been downloaded by more than 1 million people. Below is an Instagram post Exley shared in 2020, but he has since deleted his account.
Here is a summary of the study’s main findings:
-All five individuals had at least one brain tissue with a “pathologically significant” level of aluminum, defined as greater than or equal to 3.00 micrograms per gram of dry brain weight (μg/g dry wt). (Dr. Exley and colleagues developed categories to classify aluminum-related pathology after conducting other brain studies, wherein older adults who died healthy had less than 1 μg/g dry wt of brain aluminum.)
-Roughly two-thirds (67%) of all the tissue samples displayed a pathologically significant aluminum content.
Aluminum levels were particularly high in the male brains, including in a 15-year-old boy with ASD who had the study’s single highest brain aluminum measurement (22.11 μg/g dry wt)—many times higher than the pathologically significant threshold and far greater than levels that might be considered as acceptable even for an aged adult.
-Some of the elevated aluminum levels rivaled the very high levels historically reported in victims of dialysis encephalopathy syndrome (a serious iatrogenic disorder resulting from aluminum-containing dialysis solutions).
-In males, most aluminum deposits were inside cells (80/129), whereas aluminum deposits in females were primarily extracellular (15/21). The majority of intracellular aluminum was inside non-neuronal cells (microglia and astrocytes).
-Aluminum was present in both grey matter (88 deposits) and white matter (62 deposits). (The brain’s grey matter serves to process information, while the white matter provides connectivity.)
-The researchers also identified aluminum-loaded lymphocytes in the meninges (the layers of protective tissue that surround the brain and spinal cord) and in similar inflammatory cells in the vasculature, furnishing evidence of aluminum’s entry into the brain “via immune cells circulating in the blood and lymph” and perhaps explaining how youth with ASD came to acquire such shockingly high levels of brain aluminum.
Following up this paper, Exely published a paper titled “The role of aluminum adjuvants in vaccines raises issues that deserve independent, rigorous and honest science.” In their publication, they provide evidence for their position that “the safety of aluminium-based vaccine adjuvants, like that of any environmental factor presenting a risk of neurotoxicity and to which the young child is exposed, must be seriously evaluated without further delay, particularly at a time when the CDC is announcing a still increasing prevalence of autism spectrum disorders, of 1 child in 54 in the USA.”
A paper where Exely was lead author, published in Nature titled “Aluminium in human brain tissue from donors without neurodegenerative disease: A comparison with Alzheimer’s disease, multiple sclerosis and autism” shows aluminum content in brain tissue of patients with these diseases is significantly higher than healthy controls.
In the interview below, Exley answers a lot of questions, but the part that caught my attention was the following,
We have looked at what happens to the aluminum adjuvant when it’s injected and we have shown that certain types of cells come to the injection site and take up the aluminum inside them. You know, these same cells we also see in the brain tissue in autism. So, for the first time we have a link that honestly I had never expected to find between aluminum as an adjuvant in vaccines and that same aluminum potentially could be carried by those same cells across the blood brain barrier into the brain tissue where it could deposit the aluminum and produce a disease, Encephalopathy (brain damage), it could produce the more severe and disabling form of autism. This is a really shocking finding for us.
The interview is quite informative with regards to aluminum toxicology in general, but if you’re interested in the quote above, you can fast forward to the twelve minutes and thirty second mark. Here he address whether or not there’s a difference between ingested aluminum and injected aluminum.https://www.youtube.com/embed/Ju4-lKwQ4ak?feature=oembed
Is there a difference between ingested aluminum and injected aluminum?
There are many concerns being raised about aluminum in vaccines, and where that aluminum goes when it’s injected into the body. Multiple animal studies have now shown that when you inject aluminum, it may not exit the body and instead travel to distant organs and eventually ends up in the brain where it’s detectable 1-10 years after injection. When we take in aluminum from our food however, the body does a great job of getting rid of it.
This is key.
Dr. Christopher Shaw, a professor at the University of British Columbia in Canada explains,
When you inject aluminum, it goes into a different compartment of your body. It doesn’t come into that same mechanism of excretion. So, and of course it can’t because that’s the whole idea of aluminum adjuvants, aluminum adjuvants are meant to stick around and allow that antigen to be presented over and over and over again persistently, otherwise you wouldn’t put an adjuvant in in the first place. It can’t be inert, because if it were inert it couldn’t do the things it does. It can’t be excreted because again it couldn’t provide that prolonged exposure of the antigen to your immune system.
A study published in BioMed Central (also cited in the study above)in 2013 found more cause for concern:
Intramuscular injection of alum-containing vaccine was associated with the appearance of aluminum deposits in distant organs, such as spleen and brain where they were still detected one year after injection. Both fluorescent materials injected into muscle translocated to draining lymph nodes (DLNs) and thereafter were detected associated with phagocytes in blood and spleen. Particles linearly accumulated in the brain up to the six-month endpoint; they were first found in perivascular CD11b+ cells and then in microglia and other neural cells. DLN ablation dramatically reduced the biodistribution. Cerebral translocation was not observed after direct intravenous injection, but significantly increased in mice with chronically altered blood-brain-barrier. Loss/gain-of-function experiments consistently implicated CCL2 in systemic diffusion of Al-Rho particles captured by monocyte-lineage cells and in their subsequent neurodelivery. Stereotactic particle injection pointed out brain retention as a factor of progressive particle accumulation…
The study went on to conclude that “continuously escalating doses of this poorly biodegradable adjuvant in the population may become insidiously unsafe.”
These authors followed up and published a study in 2015 that emphasized:
Evidence that aluminum-coated particles phagocytozed in the injected muscle and its draining lymph nodes can disseminate within phagocytes throughout the body and slowly accumulate in the brain further suggests that alum safety should be evaluated in the long term.
Furthermore, federal health regulatory agencies have not appropriately studied the aluminum adjuvants mechanisms of action after injection, it’s simply been presumed safe after more than 90 years of use in various vaccines.
These days, science is not science, and the industry has a big influence on what science gets attention, and what science remains unacknowledged. We’ve seen this happen with COVID, for example. Cardiologist and NHS consultant Dr. Aseem Malhotra appeared on GBN News speaking about an American Heart Association study. The study found an increase risk of heart problems after COVID vaccinations. He mentions that another study found the same issue, but the researchers won’t publish it in fear of losing funding from drug companies.
Something to think about.